Literature DB >> 8635858

Immunohistochemical localization of urokinase-type plasminogen activator, type-1 plasminogen-activator inhibitor, urokinase receptor and alpha(2)-macroglobulin receptor in human breast carcinomas.

L Christensen1, A C Wiborg Simonsen, C W Heegaard, S K Moestrup, J A Andersen, P A Andreasen.   

Abstract

We have investigated the localization of urokinase-type plasminogen activator (u-PA), type-1 plasminogen-activator inhibitor (PAI-1), u-PA receptor (u-PAR) and alpha(2)-macroglobulin- receptor/low-density-lipoprotein-receptor-related protein (alpha(2)MR/LRP) in human breast tumors by immunohistochemical methods. Frozen sections of 133 primary breast carcinomas, 6 ductal carcinomas in situ and 33 lymph-node metastases were stained with monoclonal antibodies. Formalin-fixed sections of 15 primary tumors and 2 lymph-node metastases were stained with polyclonal antibodies. In primary tumors, u-PA and PAI-1 immunoreactivities were intense in macrophages and mast cells, and moderate in benign and malignant epithelial cells as well as in myofibroblasts and endothelial cells. A sub-group of poorly differentiated tumors showed particularly strong staining of stromal fibroblasts. u-PA immunoreactivity was also present in lymphocytes. alpha(2)MR/LRP and u-PAR immunoreactivities were intense in macrophages, but apart from these cells, alpha(2)MR/LRP was found only in fibroblasts, and u-PAR only in tumor cells located peripherally in tumor-cell clusters and glands and some myofibroblasts in the adjacent stroma. Lymph-node metastases showed staining for u-PA and PAI-1 both of cancer cells and of stromal fibroblasts, also staining for u-PA of lymphocytes. Similarly to some of the poorly differentiated primary tumors, approximately half of the metastases showed very strong staining of stromal fibroblasts, and extracts of these metastases had higher u-PA and PAI-1 levels, as determined by ELISA, than extracts of metastases without this staining pattern. alpha(2)MR/LRP was present only in fibroblasts and u-PAR only in some tumor cells. The presence of u-PA, PAI-1, alpha(2)MR/LRP and u-PAR was controlled biochemically by immunoblotting analyses, ligand-blotting analyses, and direct and reverse zymography. The spatial distribution and the variation in concentration of the various components of the plasminogen-activation system point to a complex, multifunctional role for the 4 proteins in and/or during the development and spread of breast cancer.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8635858     DOI: 10.1002/(SICI)1097-0215(19960516)66:4<441::AID-IJC6>3.0.CO;2-W

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  24 in total

Review 1.  The plasmin cascade and matrix metalloproteinases in non-small cell lung cancer.

Authors:  G Cox; W P Steward; K J O'Byrne
Journal:  Thorax       Date:  1999-02       Impact factor: 9.139

2.  Immunohistochemical expression of uPA, uPAR, and PAI-1 in breast carcinoma. Fibroblastic expression has strong associations with tumor pathology.

Authors:  E Dublin; A Hanby; N K Patel; R Liebman; D Barnes
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

Review 3.  LDL receptor-related protein 1: unique tissue-specific functions revealed by selective gene knockout studies.

Authors:  Anna P Lillis; Lauren B Van Duyn; Joanne E Murphy-Ullrich; Dudley K Strickland
Journal:  Physiol Rev       Date:  2008-07       Impact factor: 37.312

4.  Low density lipoprotein receptor-related protein-1 (LRP1) regulates thrombospondin-2 (TSP2) enhancement of Notch3 signaling.

Authors:  He Meng; Xiaojie Zhang; Soo Jung Lee; Dudley K Strickland; Daniel A Lawrence; Michael M Wang
Journal:  J Biol Chem       Date:  2010-05-14       Impact factor: 5.157

5.  PAI-1 mediates the TGF-beta1+EGF-induced "scatter" response in transformed human keratinocytes.

Authors:  Jennifer Freytag; Cynthia E Wilkins-Port; Craig E Higgins; Stephen P Higgins; Rohan Samarakoon; Paul J Higgins
Journal:  J Invest Dermatol       Date:  2010-04-29       Impact factor: 8.551

6.  Promigratory effect of plasminogen activator inhibitor-1 on invasive breast cancer cell populations.

Authors:  Bénédicte Chazaud; Rémy Ricoux; Christo Christov; Anne Plonquet; Romain K Gherardi; Georgia Barlovatz-Meimon
Journal:  Am J Pathol       Date:  2002-01       Impact factor: 4.307

7.  Biochemical and structural analyses suggest that plasminogen activators coevolved with their cognate protein substrates and inhibitors.

Authors:  Agnieszka Jendroszek; Jeppe B Madsen; Andrés Chana-Muñoz; Daniel M Dupont; Anni Christensen; Frank Panitz; Ernst-Martin Füchtbauer; Simon C Lovell; Jan K Jensen
Journal:  J Biol Chem       Date:  2019-01-16       Impact factor: 5.157

8.  The RNA-binding zinc-finger protein tristetraprolin regulates AU-rich mRNAs involved in breast cancer-related processes.

Authors:  N Al-Souhibani; W Al-Ahmadi; J E Hesketh; P J Blackshear; K S A Khabar
Journal:  Oncogene       Date:  2010-05-24       Impact factor: 9.867

9.  Vitamin D3 modulation of plasminogen activator inhibitor type-1 in human breast carcinomas under organ culture.

Authors:  Edson Mantovani Barbosa; Sueli Nonogaki; Maria Lucia Hirata Katayama; Maria Aparecida Azevedo Koike Folgueira; Venâncio Ferreira Avancini Alves; Maria Mitzi Brentani
Journal:  Virchows Arch       Date:  2003-12-02       Impact factor: 4.064

10.  The myofibroblast is the predominant plasminogen activator inhibitor-1-expressing cell type in human breast carcinomas.

Authors:  Birgitte Vrou Offersen; Boye Schnack Nielsen; Gunilla Høyer-Hansen; Fritz Rank; Stephen Hamilton-Dutoit; Jens Overgaard; Peter A Andreasen
Journal:  Am J Pathol       Date:  2003-11       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.